47
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa

      , , , , ,
      Vaccine
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          This study was designed to answer the question of whether a cervical cancer prevention programme that incorporates a human papillomavirus (HPV) vaccine is potentially more cost-effective than the current strategy of screening alone in South Africa. We developed a static Markov state transition model to describe the screening and management of cervical cancer within the South African context. The incremental cost-effectiveness ratio of adding HPV vaccination to the screening programme ranged from US $1078 to 1460 per quality-adjusted life year (QALY) gained and US$3320-4495 per life year saved, mainly depending on whether the study was viewed from a health service or a societal perspective. Using discounted costs and benefits, the threshold analysis indicated that a vaccine price reduction of 60% or more would make the vaccine plus screening strategy more cost-effective than the screening only approach. To address the issue of affordability and cost-effectiveness, the pharmaceutical companies need to make a commitment to price reductions.

          Related collections

          Author and article information

          Journal
          Vaccine
          Vaccine
          Elsevier BV
          0264410X
          October 2009
          October 2009
          : 27
          : 44
          : 6196-6202
          Article
          10.1016/j.vaccine.2009.08.004
          19698807
          951fb881-71d4-43b6-bdde-01e546da433f
          © 2009

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article